|
Video: What is a Stock Split?
|
|
BELLUS Health is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Co.'s primary product candidate, BLU-5937, is a selective and potentially antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. Co. is developing BLU-5937 for the treatment of adults with RCC. According to our BLU stock split history records, BLU has had 0 splits. | |
|
BLU (BLU) has 0 splits in our BLU stock split history database.
Looking at the BLU stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BLU shares, starting with a $10,000 purchase of BLU, presented on a split-history-adjusted basis factoring in the complete BLU stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
06/28/2023 |
|
Start price/share: |
$0.77 |
|
End price/share: |
$14.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
1,814.29% |
|
Average Annual Total Return: |
37.96% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$191,381.72 |
|
Years: |
9.17 |
|
|
|
|
|